170 related articles for article (PubMed ID: 32425386)
21. Age as a major factor associated with zinc and copper deficiencies in pediatric thalassemia.
Nimkarn N; Songdej D; Dumrongwongsiri O; Sirachainan N; Chuansumrit A;
J Trace Elem Med Biol; 2021 Dec; 68():126817. PubMed ID: 34298330
[TBL] [Abstract][Full Text] [Related]
22. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
Shash H
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia.
Ansari SH; Ansari I; Wasim M; Sattar A; Khawaja S; Zohaib M; Hussain Z; Adil SO; Ansari AH; Ansari UH; Farooq F; Masqati NU
Blood Adv; 2022 Dec; 6(24):6162-6168. PubMed ID: 35477175
[TBL] [Abstract][Full Text] [Related]
24. Unraveling Impact of Hemoglobin F and A2 Levels: Correlation With Disease Severity and Treatment Response in Transfusion-Dependent Beta-Thalassemia.
Nawaz K; Khan SN; Bashir A; Rehman A; Tariq Masood Khan M; Mir A; Ahmad S
Cureus; 2024 Jan; 16(1):e52002. PubMed ID: 38344549
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and Risk Factors for Cardiac and Liver Iron Overload in Adults with Thalassemia in Malaysia.
Ngim CF; Lee MY; Othman N; Lim SM; Ng CS; Ramadas A
Hemoglobin; 2019 Mar; 43(2):95-100. PubMed ID: 31179787
[TBL] [Abstract][Full Text] [Related]
26. The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with Non-Transfusion-Dependent Thalassemia.
Ricchi P; Costantini S; Spasiano A; De Dominicis G; Di Matola T; Cinque P; Ammirabile M; Marsella M; Filosa A
Blood Cells Mol Dis; 2016 Mar; 57():97-9. PubMed ID: 26810455
[TBL] [Abstract][Full Text] [Related]
27. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R
Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Thalidomide and Hydroxyurea Combination in Beta Thalassemia Patients.
Garg A; Patel K; Shah K; Trivedi D; Raj A; Yadav R; Shah S
Indian J Hematol Blood Transfus; 2023 Jan; 39(1):85-89. PubMed ID: 36699430
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide has a significant effect in patients with thalassemia intermedia.
Li Y; Ren Q; Zhou Y; Li P; Lin W; Yin X
Hematology; 2018 Jan; 23(1):50-54. PubMed ID: 28718348
[TBL] [Abstract][Full Text] [Related]
30. The long-term efficacy in blood transfusions, hematologic parameter changes, and complications after splenectomy in patients with transfusion-dependent thalassemia.
Osataphan N; Dumnil S; Tantiworawit A; Punnachet T; Hantrakun N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Fanhchaksai K; Charoenkwan P
Transfus Apher Sci; 2023 Jun; 62(3):103620. PubMed ID: 36509632
[TBL] [Abstract][Full Text] [Related]
31. Metformin as a Fetal Hemoglobin Inducer in Non-transfusion Dependent Thalassemia Patients.
ElTagui M; El-Ghamrawy M; AlDeeb SK; Nassim MS
Indian J Hematol Blood Transfus; 2024 Jan; 40(1):68-73. PubMed ID: 38312174
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial.
Chen JM; Zhu WJ; Liu J; Wang GZ; Chen XQ; Tan Y; Xu WW; Qu LW; Li JY; Yang HJ; Huang L; Cai N; Wang WD; Huang K; Xu JQ; Li GH; He S; Luo TY; Huang Y; Liu SH; Wu WQ; Lu QY; Zhou MG; Chen SY; Li RL; Hu ML; Huang Y; Wei JH; Li JM; Chen SJ; Zhou GB
Signal Transduct Target Ther; 2021 Nov; 6(1):405. PubMed ID: 34795208
[TBL] [Abstract][Full Text] [Related]
33. Effects of Thalidomide on Erythropoiesis and Iron Homeostasis in Transfusion-Dependent β-Thalassemia.
Yang K; Liu X; Peng W; Hua F; Li L; Chen K; Zhang J; Luo S; Li W; Ding Y; Chen J; Xiao J
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024001. PubMed ID: 38223482
[TBL] [Abstract][Full Text] [Related]
34. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life with standard and curative therapies in thalassemia: A narrative literature review.
Shah R; Badawy SM
Ann N Y Acad Sci; 2024 Feb; 1532(1):50-62. PubMed ID: 38270933
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan.
Akram S; Khan Khattak SA; Khan MA
Cureus; 2022 Jul; 14(7):e26691. PubMed ID: 35959173
[TBL] [Abstract][Full Text] [Related]
37. The Prevalence of
Saha J; Panja A; Nayek K
Hemoglobin; 2021 May; 45(3):157-162. PubMed ID: 34060430
[TBL] [Abstract][Full Text] [Related]
38. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
39. Decision-making about gene therapy in transfusion dependent thalassemia.
Quarmyne MO; Ross D; Sinha C; Bakshi N; Boudreaux J; Krishnamurti L
BMC Pediatr; 2022 Sep; 22(1):536. PubMed ID: 36085025
[TBL] [Abstract][Full Text] [Related]
40. Severity scoring system to guide transfusion management in pediatric non-deletional HbH.
Songdej D; Tandhansakul M; Wongwerawattanakoon P; Sirachainan N; Charoenkwan P; Chuansumrit A
Pediatr Int; 2023; 65(1):e15568. PubMed ID: 37475523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
